ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2020
Multiple sclerosis management during the COVID-19 pandemic.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Occupational outcomes of people with multiple sclerosis during the COVID-19 pandemic: a systematic review with meta-analysis.Frontiers in public health · 2023Pooled it
- Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Pooled it
- The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Pooled it
- Occupational Therapy Interventions in Mental Health During Lockdown: A Scoping Review.Healthcare (Basel, Switzerland) · 2025Review
- Trauma Burden Affected People with Multiple Sclerosis During SARS-CoV-2 Pandemic.Journal of clinical medicine · 2025Article
- MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register.Journal of neurology · 2025Article
- Patient Perspectives on Healthcare Utilization During the COVID-19 Pandemic in People with Multiple Sclerosis-A Longitudinal Analysis.Healthcare (Basel, Switzerland) · 2025Article
- Socioecologies in shaping migrants and refugee youths' sexual and reproductive health and rights: a participatory action research study.Reproductive health · 2024Article
- COVID-19 and multiple sclerosis: challenges and lessons for patient care.The Lancet regional health. Europe · 2024Review
- Era of COVID-19 in Multiple Sclerosis Care.Neurologic clinics · 2024Review
- COVID-19 Vaccination Coverage and Associated Factors in Patients with Multiple Sclerosis.Vaccines · 2024Article
- Impact of COVID-19 and system recovery in delivering healthcare to people with multiple sclerosis: a population-based Study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- COVID-19 and the Pandemic-Related Aspects in Pediatric Demyelinating Disorders.Seminars in pediatric neurology · 2023Review
- Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- The influence of the COVID-19 pandemic on the prescription of multiple sclerosis medication in Germany.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- Article
- Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviors and access to disease-modifying therapies.Multiple sclerosis and related disorders · 2022Article
- Association of Race and Area Deprivation With Breast Cancer Survival Among Black and White Women in the State of Georgia.JAMA network open · 2022Article
- The impact of socioeconomic status on subsequent neurological outcomes in multiple sclerosis.Multiple sclerosis and related disorders · 2022Article
- Multiple Sclerosis Management During the COVID-19 Pandemic.Current neurology and neuroscience reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
backgroundPeople with multiple sclerosis (MS) may be at higher risk for complications from the 2019 coronavirus (COVID-19) pandemic due to use of immunomodulatory disease modifying therapies (DMTs) and greater need for medical services.
objectivesTo evaluate risk factors for COVID-19 susceptibility and describe the pandemic's impact on healthcare delivery.
methodsSurveys sent to MS patients at Cleveland Clinic, Johns Hopkins, and Vall d'Hebron-Centre d'Esclerosi Múltiple de Catalunya in April and May 2020 collected information about comorbidities, DMTs, exposures, COVID-19 testing/outcomes, health behaviors, and disruptions to MS care.
resultsThere were 3028/10,816 responders. Suspected or confirmed COVID-19 cases were more likely to have a known COVID-19 contact (odds ratio (OR): 4.38; 95% confidence interval (CI): 1.04, 18.54). In multivariable-adjusted models, people who were younger, had to work on site, had a lower education level, and resided in socioeconomically disadvantaged areas were less likely to follow social distancing guidelines. 4.4% reported changes to therapy plans, primarily delays in infusions, and 15.5% a disruption to rehabilitative services.
conclusionYounger people with lower socioeconomic status required to work on site may be at higher exposure risk and are potential targets for educational intervention and work restrictions to limit exposure. Providers should be mindful of potential infusion delays and MS care disruption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.